Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b/2a Multi-center, Open-label, Dose Escalation Study to Evaluate the Safety, Tolerability and Efficacy of MN-166 (Ibudilast) and Temozolomide Combination Treatment in Patients With Recurrent Glioblastoma

Trial Profile

Phase 1b/2a Multi-center, Open-label, Dose Escalation Study to Evaluate the Safety, Tolerability and Efficacy of MN-166 (Ibudilast) and Temozolomide Combination Treatment in Patients With Recurrent Glioblastoma

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Dec 2018

At a glance

  • Drugs Ibudilast (Primary) ; Temozolomide (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Sponsors MediciNova
  • Most Recent Events

    • 19 Dec 2018 Status changed from planning to not yet recruiting.
    • 09 May 2018 According to a MediciNova media release, the U.S. Food and Drug Administration (FDA) has accepted the IND for MN-166 in combination with temozolomide for treatment of GBM.
    • 08 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top